By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Akebia Therapeutics, Inc. 

245 First Street
Suite 1100
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-871-2098 Fax: 617-871-2099


Company News
Akebia (AKBA) Announces Second Quarter 2017 Financial Results 8/9/2017 7:28:52 AM
Akebia (AKBA) Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) 8/7/2017 6:45:33 AM
Akebia (AKBA) Announces Closing Of Public Offering Of Common Stock And Exercise Of Option By Underwriters 7/6/2017 6:40:59 AM
Akebia (AKBA) Announces Proposed Public Offering Of Common Stock 6/29/2017 6:40:00 AM
Akebia (AKBA) Announces Pricing Of Public Offering Of Common Stock 6/29/2017 6:32:17 AM
Akebia (AKBA) To Host Analyst And Investor Day On June 27, 2017 6/20/2017 6:03:10 AM
Akebia (AKBA) Prevails In Two Additional European Patent Disputes 6/5/2017 12:29:10 PM
Akebia (AKBA) Names Rita Jain, M.D. As Chief Medical Officer 5/25/2017 8:18:41 AM
Akebia (AKBA) Initiates Phase II FO2RWARD Study Of Vadadustat In Dialysis Patients With Anemia Related To Chronic Kidney Disease Hyporesponsive To Treatment With Erythropoiesis-Stimulating Agents 5/24/2017 7:26:35 AM
Akebia (AKBA) And Vifor Pharma Announce Exclusive License Agreement To Provide Vadadustat To Fresenius Medical Care In The U.S. Upon Vifor Pharma Approval 5/16/2017 7:45:59 AM